Cytoprotective and supportive care agents:
Indications for SANDOSTATIN:
Severe diarrhea and flushing due to metastatic carcinoid tumors. Profuse watery diarrhea due to vasoactive intestinal peptide-secreting tumors (VIPomas).
Adult Dosage:
Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Carcinoid tumors: 100–600mcg/day in 2–4 divided doses for first 2 weeks; usual maintenance: 450mcg/day; max 1500mcg/day. VIPomas: Initially 200–300mcg/day in 2–4 divided doses for first 2 weeks; max 750mcg/day.
Children Dosage:
Not recommended.
SANDOSTATIN Warnings/Precautions:
Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Carcinoid tumors: monitor 5-HIAA, plasma serotonin, plasma Substance P. VIPomas: perform baseline and periodic total and/or free T4 measurements with chronic therapy. Monitor thyroid function, gallbladder, glucose, vitamin B12. Pregnancy. Nursing mothers.
See Also:
SANDOSTATIN Classification:
Somatostatin analogue.
SANDOSTATIN Interactions:
Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.
Adverse Reactions:
Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, headache, dizziness, pancreatitis, back pain, inj site pain.
How Supplied:
Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (5mL vial w. supplies)
Pricing for SANDOSTATIN
Pituitary disorders:
Indications for SANDOSTATIN:
Acromegaly unresponsive to or that cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.
Adult Dosage:
Give by IV infusion over 15–30 minutes, IV push over 3 minutes, or deep SC (intrafat) inj. Initially 50mcg 3 times daily. Usual maintenance: 100micrograms 3 times daily; max 500mcg 3 times daily. Reevaluate every 6 months. Pituitary irradiation recipients: withdraw therapy for 4 weeks once yearly to assess disease activity; resume if GH or IGF-1 levels increase or signs/symptoms recur.
Children Dosage:
Not recommended.
SANDOSTATIN Warnings/Precautions:
Diabetes. Hypothyroidism. Cardiovascular disease. Renal or hepatic impairment. Monitor growth hormone, IGF-1 levels, thyroid function, gallbladder, glucose, vitamin B12. Discontinue and treat if cholelithiasis complications are suspected. Pregnancy. Nursing mothers.
See Also:
SANDOSTATIN Classification:
Somatostatin analogue.
SANDOSTATIN Interactions:
Potentiates bromocriptine, CYP450 substrates (eg, quinidine, terfenadine), bradycardia-inducing drugs (eg, β-blockers, calcium channel blockers). Antagonizes cyclosporine. Not compatible with TPN solutions. May need to adjust antidiabetic agents. May affect agents used to control fluid and electrolyte balance.
Adverse Reactions:
Gallbladder abnormalities (eg, gallstones, biliary sludge), GI upset, bradycardia, conduction abnormalities, arrhythmias, hyperglycemia, hypoglycemia, hypothyroidism, headache, dizziness, pancreatitis, back pain, inj site pain.
How Supplied:
Ampules 50mcg/mL, 100mcg/mL, 500mcg/mL (1mL)—10; LAR kit—1 (5mL vial w. supplies)
